Comparison of KIR and KIR ligand genotype frequencies between patients recurring vs. those who did not.

<p>*: Combination of Group C and any cognate inhibitory KIR</p><p>Comparison of KIR and KIR ligand genotype frequencies between patients recurring vs. those who did not.</p

Characteristics of patients.

<p>n.s.: non significant</p><p>Characteristics of patients.</p

Influence of number of activating KIRs on Disease Free Survival: none vs. one vs. two activating KIRs.

<p>Patients who have two activating KIRs in their genotype have longer DFS compared to those who have one activating KIR. Patients who lack any activating KIR have the shortest DFS: no KIR: 54 months (CI: 42–65); one KIR: 77 months (CI: 61–92); two KIRs: 98 months (CI: 87–108) (p = 0.004). X axis shows percentage of survivors without recurrence against months of follow-up (y axis).</p

Impact of inhibitory (2DL1, 2DL1-Group C2 and 2DL3 Group C1) (upper row) and activating (2DS2, 2DS2- Group C1 and 2DS3) (lower row) KIRs on Progression Free Survival.

<p>X axis shows percentage of survivors without recurrence against months of follow-up (y axis). The lack of inhibitory KIR2DL1, 2DL1-C2, or 2DL3-C1 improved DFS (100% vs. 62.3%, p = 0.05; 93.8% vs. 60.0%, p = 0.035; 73.6% vs. 55.9%, p = 0.07). Presence of activating KIR2DS2, 2DS2-C1 and 2DS3 (77.8% vs. 48.5%, p = 0.01; 76.9% vs. 51.4%, p = 0.023; 79.4% vs. 58.5%, p = 0.003;) are also associated with longer DFS.</p

Comparison of KIR/Ligand frequencies: local recurrence versus distant metastasis.

<p>The variables found significant after comparison of frequencies between recurrent vs. non-recurrent cases were used in this table.</p